| No Adverse Event | Major Adverse Event | p value | |
|---|---|---|---|
| Age, mean (SD) | 31.3 (7.1) | 27.3 (5.7) | 0.050 |
| Black race, n (%) | 5 (15.2) | 8 (50.0) | 0.01 |
| Hypertension, n (%) | 12 (35.3) | 6 (35.3) | 1.000 |
| Preeclampsia, n (%) | 8 (23.5) | 3 (17.6) | 0.630 |
| Diabetes mellitus, n (%) | 6 (17.6) | 4 (23.5) | 0.618 |
| Autoimmune disorder, n (%) | 0 (0.0) | 1 (5.9) | 0.153 |
| Thyroid disease, n (%) | 3 (8.8) | 2 (11.8) | 0.739 |
| EF at Diagnosis, mean (SD) | 21.0 (12.2) | 14.4 (12.0) | 0.073 |
| EF at 6 months, mean (SD) | 44.8 (17.6) | 17.7 (13.0) | <.0001 |
| EF at 12 months, mean (SD) | 45.0 (21.0) | 16.1 (9.5) | <.0001 |
| Peak EF, mean (SD) | 55.3 (14.6) | 25.9 (17.7) | <.0001 |
| Final EF, mean (SD) | 49.6 (18.1) | 16.4 (12.7) | <.0001 |
| Beta-blocker, n (%) | 31 (91.2) | 15 (88.2) | 0.739 |
| ACE-I/ARB, n (%) | 37 (93.0) | 16 (84.0) | 0.325 |
| Aldosterone Antagonist, n (%) | 22 (64.7) | 13 (76.5) | 0.393 |
| Diuretic, n (%) | 30 (88.2) | 16 (94.1) | 0.505 |
| Digoxin, n (%) | 14 (41.2) | 14 (82.4) | 0.005 |
| Bromocriptine, n (%) | 0 (0.0) | 2 (11.8) | 0.041 |
| Months of Follow up, mean (SD) | 89.4 (56.1) | 77.6 (59.6) | 0.494 |